Thiberville, SD, et al. Chikungunya fever: epidemiology, clinical syndrome, pathogenesis and therapy. Antivir Res. 2013 ;99(3):345-370.
Sahadeo N, et al. Molecular characterisation of chikungunya virus infections in Trinidad and comparison of clinical and laboratory features with dengue and other acute febrile cases. PLoS Negl Trop Dis. 2015;9(11):e0004199.
Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika viruses: A systematic review. PLoS Negl Trop Dis. 2021;15(3):e0009055.
Boggild AK. et al. Chikungunya in travellers returning to Canada: Surveillance report from CanTravNet surveillance data, 2006 to 2015. J Assoc Med Microbiol Infect Dis Can. 2016;1(3):1-16.
Suhrbier A. Rheumatic manifestations of chikungunya: emerging concepts and interventions. Nat Rev. 2019;15:597-611.
Bettis AA, et al. The global epidemiology of chikungunya from 1999 to 2020: A systematic literature review to inform the development and introduction of vaccines. PLoS Negl Trop Dis. 2022;6(1):e0010069.
Nemg Simo FB, et al. Chikungunya virus diagnosis: A review of current antigen detection methods. Trop Med Infect Dis. 2023;8(7):365.
Pathak H, et al. Chikungunya arthritis. Clin Med. 2019;19(5):381–385.
Silva L, Dermody T. Chikungunya virus: epidemiology, replication, disease mechanisms, and prospective intervention strategies.J Clin Invest. 2017;127(3):737-749.
Paixão ES, et al. Chikungunya chronic disease: a systematic review and meta-analysis. Trans R Soc Trop Med Hyg. 2018;1123(7):301-316.
Marques CDL, et al. Recommendations of the Brazilian Society of Rheumatology for diagnosis and treatment of Chikungunya fever. Part 1 – Diagnosis and special situations. Rev Bras Reumatol. 2017;57(S2):S421-S437.
Essackjee K, et al. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad Med J. 2013;89(1054):440-447.
Schneider M, et al. Safety and immunogenicity of a single-shot live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-controlled, phase 3 trial. The Lancet. 2023;401:2138–2147.
This link will take you to another website to which Valneva’s Privacy Policy does not apply. We encourage you to read the Privacy Policy of every website you visit.
Click the Cancel button to return to www.IXCHIQ.ca or OK to continue.